In 2007 the entire industry ushered in the recovery, in 2007 the first eight months of the pharmaceutical industry achieved sales of 363.1 billion yuan, up 24.73 percent, the Sphygmomanometer total volume of 33.1 billion yuan, up 48.76 percent year rapid growth is a foregone conclusion. However, the overall gross margin level of the industry is still hovering in the low cost high profit rate decreased as the main engine of growth. Son of industry, chemicals and proprietary Chinese medicines become pulling 2007 pharmaceutical industry growth of the main force.
Since 2007 growth of a higher base, so in 2008 may be the same as in recent years, after a peak to form a trough, while urban residents have medical insurance, and other new market space, but some contradictions within the industry has not fully resolved, price control, such as the rise in the cost factors still affecting the industry profit levels.
Health care reform remains the most Sphygmomanometer important impact on the pharmaceutical industry, although the current medical system reform program has not yet final, but that the supply-side subsidies and demand-side subsidies have clear ideas. The current demand-side subsidies have been gradually carried out, the medical insurance system for urban residents and the new rural medical insurance system for farmers will be given government subsidies, and health care and insurance system for urban workers and taken as a total population coverage of medical security system. The expected supply-side subsidies program will be in 2008 launched specific programs may be to subsidize basic medical institutions mainly. The program launched reform of the medical system may change China's current administration structure, and treatment of serious illness drug production of cheap generic drugs to commercial enterprises and large pharmaceutical companies will gain a greater market share.
Registration of new drugs and new management methods GMP certification inspection assessed in 2008 will be the standard in 2008 in full swing, if we can strictly enforce the law, which eliminated a number of failed businesses, the pharmaceutical industry will maintain order and promote development of pharmaceutical industry the well. In the preparation of quality production enterprises benefit from this action. Environmental pressure medicine raw materials prices will continue to stay high, but will show fluctuations, no longer like 2007's unilateral up. Environmental protection input, the ability of enterprises will continue in this process proceeds.
International capital continue to pay attention to China's pharmaceutical industry, domestic pharmaceutical enterprises is not only foreign competitors, but also the development of China's pharmaceutical industry promotion, international pharmaceutical industry to have a vision and a strategy will not be eliminated in the competition.
2007 A-share market in the pharmaceutical plate has experienced substantial fluctuations in performance due to increased investment income occupy a relatively large proportion of shares rose and many companies do not have substantial support of the performance, but with the sharp correction in stock prices , a quality company's stock has entered the investment scope.
In 2008 the market will re-evaluation of the pharmaceutical Sphygmomanometer industry, who trades in a long-distance race will be more market recognition, the sea is recommended Pharmaceutical stocks (market and the stock it), Yunnan Baiyao, Baiyunshan, Shanghai Branch, biological and medicine.
In 2007, the pharmaceutical industry out of the 2006's shadow, sales revenues and profits are realized substantial growth. In 2006 the industry made the consolidation of the industry are all potential problems floating to the surface, to find a solution to these problems, and made China's pharmaceutical industry and the health care system onto a path of healthy development, has become the consensus of all. Although the interests of disputes, the health care reform program after a year's time remains undetermined, but it is only a matter of time. Perhaps also experienced twists and turns, but has a complete industrial chain, in the face of the huge population base and consumer demand in the Chinese pharmaceutical industry, which is bound to focus on the development of the Chinese pharmaceutical industry and the capital brought handsome returns.
Since 2007 growth of a higher base, so in 2008 may be the same as in recent years, after a peak to form a trough, while urban residents have medical insurance, and other new market space, but some contradictions within the industry has not fully resolved, price control, such as the rise in the cost factors still affecting the industry profit levels.
Health care reform remains the most Sphygmomanometer important impact on the pharmaceutical industry, although the current medical system reform program has not yet final, but that the supply-side subsidies and demand-side subsidies have clear ideas. The current demand-side subsidies have been gradually carried out, the medical insurance system for urban residents and the new rural medical insurance system for farmers will be given government subsidies, and health care and insurance system for urban workers and taken as a total population coverage of medical security system. The expected supply-side subsidies program will be in 2008 launched specific programs may be to subsidize basic medical institutions mainly. The program launched reform of the medical system may change China's current administration structure, and treatment of serious illness drug production of cheap generic drugs to commercial enterprises and large pharmaceutical companies will gain a greater market share.
Registration of new drugs and new management methods GMP certification inspection assessed in 2008 will be the standard in 2008 in full swing, if we can strictly enforce the law, which eliminated a number of failed businesses, the pharmaceutical industry will maintain order and promote development of pharmaceutical industry the well. In the preparation of quality production enterprises benefit from this action. Environmental pressure medicine raw materials prices will continue to stay high, but will show fluctuations, no longer like 2007's unilateral up. Environmental protection input, the ability of enterprises will continue in this process proceeds.
International capital continue to pay attention to China's pharmaceutical industry, domestic pharmaceutical enterprises is not only foreign competitors, but also the development of China's pharmaceutical industry promotion, international pharmaceutical industry to have a vision and a strategy will not be eliminated in the competition.
2007 A-share market in the pharmaceutical plate has experienced substantial fluctuations in performance due to increased investment income occupy a relatively large proportion of shares rose and many companies do not have substantial support of the performance, but with the sharp correction in stock prices , a quality company's stock has entered the investment scope.
In 2008 the market will re-evaluation of the pharmaceutical Sphygmomanometer industry, who trades in a long-distance race will be more market recognition, the sea is recommended Pharmaceutical stocks (market and the stock it), Yunnan Baiyao, Baiyunshan, Shanghai Branch, biological and medicine.
In 2007, the pharmaceutical industry out of the 2006's shadow, sales revenues and profits are realized substantial growth. In 2006 the industry made the consolidation of the industry are all potential problems floating to the surface, to find a solution to these problems, and made China's pharmaceutical industry and the health care system onto a path of healthy development, has become the consensus of all. Although the interests of disputes, the health care reform program after a year's time remains undetermined, but it is only a matter of time. Perhaps also experienced twists and turns, but has a complete industrial chain, in the face of the huge population base and consumer demand in the Chinese pharmaceutical industry, which is bound to focus on the development of the Chinese pharmaceutical industry and the capital brought handsome returns.